CIK 0001601830 · Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464099738
- Phone
- (385) 269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-09 | Gibson Christopher Director | Conversion 10b5-1 | +20,000 | 926,556 | ||
| 2026-03-09 | Gibson Christopher Director | Gift 10b5-1 | −20,000 | 906,556 | ||
| 2026-03-09 | Gibson Christopher Director | Conversion · Class B Common Stock 10b5-1 | −20,000 | 4,523,334 | ||
| 2026-03-09 | Khan Najat CEO and President | Sale 10b5-1 | −28,298 | $3.35 | $95K | 2,262,085 |
| 2026-03-03 | Borgeson Blake Director | Sale 10b5-1 | −170,000 | $3.46 | $588K | 6,259,863 |
| 2026-02-19 | Gibson Christopher Director | Conversion 10b5-1 | +40,000 | 946,556 | ||
| 2026-02-19 | Gibson Christopher Director | Sale 10b5-1 | −40,000 | $3.46 | $138K | 906,556 |
| 2026-02-19 | Gibson Christopher Director | Conversion · Class B Common Stock 10b5-1 | −40,000 | 4,543,334 | ||
| 2026-02-18 | Taylor Ben R Chief Financial Officer | Sale 10b5-1 | −13,426 | $3.08 | $41K | 1,195,349 |
| 2026-02-17 | Hallett David Chief Scientific Officer | Shares withheld for taxes | −11,908 | $3.49 | $42K | 1,097,151 |
| 2026-02-17 | Gibson Christopher Director | Shares withheld for taxes 10b5-1 | −27,265 | $3.49 | $95K | 906,556 |
| 2026-02-17 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes 10b5-1 | −11,908 | $3.49 | $42K | 1,208,775 |
| 2026-02-17 | Khan Najat CEO and President | Shares withheld for taxes | −14,280 | $3.49 | $50K | 2,290,383 |
| 2026-02-06 | Khan Najat CEO and President | Grant or award | +1,673,546 | 2,284,681 | ||
| 2026-02-06 | Khan Najat CEO and President | Grant or award | +30,346 | 2,315,027 | ||
| 2026-02-06 | Khan Najat CEO and President | Shares withheld for taxes | −10,364 | $3.98 | $41K | 2,304,663 |
| 2026-02-06 | Taylor Ben R Chief Financial Officer | Grant or award | +446,279 | 1,207,829 | ||
| 2026-02-06 | Taylor Ben R Chief Financial Officer | Grant or award | +24,254 | 1,232,083 | ||
| 2026-02-06 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −11,400 | $3.98 | $45K | 1,220,683 |
| 2026-02-06 | Hallett David Chief Scientific Officer | Grant or award | +502,064 | 1,096,205 |
Page 4 of 9 · 179 trades